Browse 100+ evidence-based profiles with community ratings, dosage guides, and safety information.
Start ExploringPublished 20 March 2026
Selank is a synthetic peptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as a novel anxiolytic agent with cognitive-enhancing properties. Structurally derived from the endogenous immunomodulatory peptide tuftsin, Selank has been the subject of extensive preclinical and clinical research in Russia, where it received regulatory approval as a prescription anxiolytic and nootropic medication. Unlike benzodiazepines - the conventional pharmacological treatment for anxiety - Selank does not produce sedation, cognitive impairment, tolerance, or physical dependence, making it a compelling option for those seeking relief from anxiety without the significant drawbacks of traditional anxiolytic drugs.
What sets Selank apart from many other nootropic compounds is the breadth and depth of its pharmacological profile. It simultaneously modulates GABAergic neurotransmission, influences serotonin metabolism, upregulates brain-derived neurotrophic factor (BDNF) expression, stabilises endogenous opioid peptides, and exerts immunomodulatory effects. This multi-target mechanism of action means that Selank does not simply suppress anxiety through a single receptor interaction - it addresses the neurochemical landscape that gives rise to anxiety while simultaneously supporting cognitive function and immune health. This guide examines the scientific evidence behind Selank's mechanisms, benefits, dosing protocols, and practical considerations for use.
Selank (TP-7) is a heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed in the 1990s by a research team led by Nikolai Myasoedov at the Institute of Molecular Genetics of the Russian Academy of Sciences, in collaboration with the V.V. Zakusov Research Institute of Pharmacology. The peptide was designed by taking the active fragment of tuftsin - a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by enzymatic cleavage of the Fc region of immunoglobulin G - and attaching a stabilising Pro-Gly-Pro tripeptide sequence to its C-terminus. This modification dramatically improves metabolic stability, extending the peptide's half-life from seconds (tuftsin is rapidly degraded by peptidases) to several minutes, which is sufficient for pharmacological activity when administered intranasally.
Tuftsin itself was first described by Victor Najjar in the 1970s as a natural phagocytosis-stimulating peptide involved in innate immune function. By building upon tuftsin's structure, the developers of Selank created a compound that retains immunomodulatory properties while gaining pronounced anxiolytic and nootropic effects. The dual nature of Selank - acting on both the nervous system and the immune system - reflects its unique origin as a hybrid of immunology and neuropharmacology.
In Russia, Selank is approved and marketed under the brand name Selanc as a nasal spray formulation (0.15% solution) for the treatment of generalised anxiety disorder and as an adjunctive treatment for enhancing cognitive function. It holds the status of a registered pharmaceutical product in the Russian Federation and has been prescribed clinically since the early 2010s. Outside of Russia, Selank has not undergone the regulatory approval process required by the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), or the UK Medicines and Healthcare products Regulatory Agency (MHRA), and it remains an unregistered research compound in Western countries.
Selank's anxiolytic and nootropic effects arise from its influence on multiple neurotransmitter systems and neurobiological pathways. Unlike single-target drugs such as benzodiazepines (which act exclusively at GABA-A receptors), Selank engages a network of mechanisms that collectively reduce anxiety, enhance cognitive resilience, and support neuroplasticity. The following subsections examine each mechanism in detail.
Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the central nervous system, and deficient GABAergic tone is one of the most well-established neurochemical correlates of anxiety disorders. Selank enhances GABAergic neurotransmission through several complementary pathways. Research published in Bulletin of Experimental Biology and Medicine demonstrated that Selank increases the binding affinity of GABA to GABA-A receptors, effectively making the existing GABAergic system more sensitive and responsive to its own signalling molecules. This is mechanistically distinct from benzodiazepines, which act as positive allosteric modulators that directly potentiate GABA-A receptor activity regardless of endogenous GABA levels.
Additionally, studies using microdialysis in animal models have shown that Selank increases the concentration of GABA in the hippocampus and hypothalamus - brain regions critically involved in anxiety processing, stress responses, and memory consolidation. By both increasing GABA availability and enhancing receptor sensitivity, Selank achieves anxiolytic effects that are functionally comparable to benzodiazepines in magnitude but fundamentally different in character. There is no overshoot into sedation, no impairment of motor coordination, and no evidence of receptor downregulation with repeated use - problems that plague benzodiazepine therapy.
Selank exerts significant effects on the serotonergic system, though its mechanism is distinct from that of selective serotonin reuptake inhibitors (SSRIs). Research conducted at the Institute of Molecular Genetics demonstrated that Selank influences the metabolism of serotonin (5-HT) by modulating the activity of enzymes involved in serotonin synthesis and degradation. Specifically, Selank has been shown to stabilise the ratio of serotonin to its primary metabolite, 5-hydroxyindoleacetic acid (5-HIAA), suggesting that it smooths out fluctuations in serotonin turnover rather than simply increasing or decreasing serotonin levels.
A study published in Zhurnal Vysshei Nervnoi Deyatelnosti (Journal of Higher Nervous Activity) found that Selank differentially affected serotonin metabolism in the hippocampus, hypothalamus, and frontal cortex - regions that play key roles in mood regulation, stress response, and executive function. The stabilisation of serotonin metabolism is thought to contribute to Selank's mood-stabilising effects and its ability to reduce the emotional reactivity that characterises anxiety disorders. Unlike SSRIs, which take 4-6 weeks to reach full efficacy due to the time required for serotonin receptor desensitisation, Selank's effects on serotonin metabolism appear to manifest more rapidly, consistent with the relatively fast onset of its anxiolytic action observed in clinical practice.
Brain-derived neurotrophic factor (BDNF) is a critical protein that supports the survival of existing neurons, promotes the growth and differentiation of new neurons, and facilitates synaptic plasticity - the process by which neural connections are strengthened or weakened in response to experience. Low BDNF levels are consistently associated with depression, anxiety disorders, and cognitive decline, while interventions that increase BDNF (exercise, certain medications, and specific nootropics) tend to improve mood, memory, and learning capacity.
Research by Inozemtseva et al. published in Doklady Biological Sciences demonstrated that Selank significantly upregulates the expression of the BDNF gene in the hippocampus of rats. This effect was accompanied by enhanced long-term potentiation (LTP) - the cellular mechanism underlying memory formation - and improved performance in learning and memory tasks. A subsequent study confirmed that Selank also influences the expression of other neurotrophic factors, including nerve growth factor (NGF) and TrkB receptors (the primary receptor for BDNF), suggesting a broad pro-neuroplastic effect. The upregulation of BDNF may be particularly relevant for Selank's cognitive-enhancing properties, as it provides a molecular basis for improved learning, memory consolidation, and adaptive responses to stress.
Selank's immunomodulatory properties are a direct inheritance from its parent molecule, tuftsin. Tuftsin is a well-characterised stimulator of phagocytosis, natural killer cell activity, and macrophage function - key components of the innate immune system. Selank retains these properties while adding modulatory effects on adaptive immunity through its influence on cytokine expression.
Studies have demonstrated that Selank modulates the expression of a broad panel of cytokines, including interleukin-6 (IL-6), a pleiotropic cytokine involved in both pro-inflammatory and anti-inflammatory signalling. Importantly, Selank appears to act as a true immunomodulator rather than a simple immunostimulant - it can both upregulate and downregulate immune responses depending on the baseline immune state. Research published in Immunology Letters showed that Selank shifted cytokine profiles towards a more balanced state, reducing excessive inflammation while maintaining appropriate immune surveillance. This is particularly relevant given the growing understanding that neuroinflammation and peripheral immune dysregulation contribute to anxiety disorders, depression, and cognitive dysfunction. The bidirectional relationship between the immune system and the nervous system - the so-called neuro-immune axis - means that Selank's immunomodulatory effects may indirectly support its neuropsychiatric benefits.
Enkephalins are endogenous opioid peptides that play important roles in pain modulation, stress responses, and emotional regulation. Under normal conditions, enkephalins are rapidly degraded by peptidases, particularly enkephalinase (neutral endopeptidase) and aminopeptidase N, giving them a very short duration of action. Selank has been shown to inhibit the activity of these enkephalin-degrading enzymes, effectively extending the lifespan and activity of endogenous enkephalins in the brain.
This mechanism is significant because enkephalins exert anxiolytic and mood-enhancing effects through their action at delta-opioid receptors. By stabilising enkephalins rather than directly activating opioid receptors, Selank achieves opioidergic enhancement without the risks of exogenous opioid agonism - namely tolerance, dependence, respiratory depression, and euphoria. The enkephalin-stabilising effect may also contribute to Selank's ability to improve stress resilience and emotional well-being, as the endogenous opioid system is fundamentally involved in the regulation of hedonic tone and the experience of reward.
Anxiety reduction is Selank's primary and best-documented benefit. Clinical trials conducted in Russia have demonstrated that Selank produces anxiolytic effects comparable in magnitude to those of benzodiazepines such as phenazepam (a commonly prescribed anxiolytic in Russian medicine), without the sedation, cognitive impairment, or dependence liability associated with that drug class. A randomised controlled trial published in Zhurnal Nevrologii i Psikhiatrii compared Selank nasal spray to phenazepam in patients with generalised anxiety disorder over a 14-day treatment period and found equivalent reductions in anxiety scores on standardised rating scales, with significantly fewer side effects in the Selank group.
The anxiolytic mechanism of Selank is multifaceted, involving GABAergic enhancement, serotonin stabilisation, enkephalin preservation, and BDNF upregulation. This multi-target approach may explain why Selank appears to address different aspects of anxiety simultaneously - the somatic symptoms (muscle tension, restlessness), the cognitive symptoms (worry, rumination), and the emotional symptoms (dread, fear) - whereas single-target anxiolytics often address only one dimension effectively. Patients in clinical studies have reported a calm, clear-headed state rather than the dulled, sedated feeling associated with benzodiazepines.
One of Selank's most distinctive benefits is its ability to preserve and even enhance cognitive function under conditions of stress. Stress is well known to impair working memory, attention, and executive function through cortisol-mediated disruption of prefrontal cortex activity and hippocampal function. Selank appears to buffer against these stress-induced cognitive deficits, allowing individuals to maintain mental performance during high-pressure situations.
Preclinical studies have demonstrated that Selank prevents stress-induced impairments in learning and memory in animal models subjected to various stress paradigms, including restraint stress and inescapable foot shock. A clinical study in patients with anxiety disorders found that Selank improved attention and memory scores on psychometric testing, with the greatest improvements observed in those with the highest baseline anxiety levels. This suggests that Selank's cognitive benefits are not merely a secondary consequence of anxiety reduction but involve direct nootropic mechanisms - most likely BDNF upregulation and stabilisation of monoamine neurotransmission in prefrontal and hippocampal circuits.
Users of Selank frequently report enhanced mental clarity, improved concentration, and a greater ability to sustain attention on demanding tasks. While subjective reports must be interpreted cautiously, they are consistent with the compound's known pharmacological effects. By reducing the intrusive cognitive noise generated by anxiety (worry loops, threat monitoring, hypervigilance), Selank frees up attentional resources that can be directed towards the task at hand. Simultaneously, its pro-BDNF effects and serotonergic stabilisation support the prefrontal cortical circuits responsible for sustained attention and cognitive control.
This benefit is particularly relevant for individuals whose attention difficulties are secondary to anxiety. Many people experience concentration problems not because of an intrinsic attentional deficit but because anxiety commandeers their cognitive resources. For these individuals, an anxiolytic that also supports cognition - rather than one that impairs it, as benzodiazepines do - represents a meaningful functional improvement.
Selank's influence on serotonin metabolism, BDNF expression, and enkephalin stability collectively contribute to a mood-stabilising effect. Clinical observations from Russian prescribing practice report that patients using Selank experience fewer mood fluctuations, reduced emotional reactivity, and improved emotional resilience. This is not a euphoric or mood-elevating effect - Selank does not produce the "high" associated with stimulants or recreational substances - but rather a normalisation of emotional responses.
The mood-stabilising property is thought to be particularly valuable for individuals with comorbid anxiety and depressive symptoms, a common clinical presentation. By addressing the neurochemical overlap between anxiety and depression (shared deficits in serotonin, BDNF, and GABAergic tone), Selank may provide broader symptomatic relief than compounds that target only one of these conditions.
As a derivative of tuftsin, Selank retains meaningful immunomodulatory properties. Russian clinical literature describes its use as an adjunctive treatment during periods of immune challenge, with studies demonstrating enhanced phagocytic activity, normalised cytokine profiles, and improved immune surveillance in Selank-treated subjects. A clinical trial in patients with weakened immune function found that Selank nasal spray improved immunological parameters and reduced the frequency and duration of upper respiratory infections.
While the immune-supporting effects are often considered secondary to its neuropsychiatric benefits, they add practical value - particularly given that chronic stress and anxiety are themselves immunosuppressive. By both reducing anxiety (thereby lifting the immunosuppressive burden of chronic stress) and directly supporting immune function, Selank addresses the bidirectional relationship between psychological stress and immune health.
Selank is most commonly administered as a nasal spray, which is the route used in the approved Russian pharmaceutical formulation and in the majority of clinical studies. The nasal mucosa provides rapid absorption of peptides into the bloodstream and, via the olfactory pathway, relatively direct access to the central nervous system - a key advantage for a peptide that must reach brain tissue to exert its effects.
It is important to note that these dosing protocols are derived primarily from Russian medical literature and clinical practice. Western clinical trials have not been conducted at the scale necessary to independently verify optimal dosing, and individual responses may vary. As with any peptide, storage conditions matter - Selank should be stored refrigerated (2-8 degrees Celsius) once reconstituted, and protected from light and heat to prevent degradation.
Selank and Semax are the two most prominent peptide nootropics to emerge from Russian neuropharmacological research, and they are frequently discussed together. Both were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, both are approved pharmaceuticals in Russia, and both are administered as nasal sprays. However, they differ substantially in their primary mechanisms of action, subjective effects, and clinical applications.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analogue of adrenocorticotrophic hormone (ACTH) fragment 4-10, with a Pro-Gly-Pro stabilising sequence identical to that used in Selank. Where Selank is primarily anxiolytic and calming, Semax is primarily stimulating and cognitive-enhancing. Semax's principal mechanisms involve upregulation of BDNF (to an even greater extent than Selank), dopaminergic modulation, and serotonergic enhancement. It is used clinically in Russia for stroke recovery, cognitive impairment, and as a nootropic for healthy individuals seeking enhanced mental performance.
| Property | Selank | Semax |
|---|---|---|
| Origin peptide | Tuftsin (immunomodulatory) | ACTH 4-10 (neuroendocrine) |
| Primary effect | Anxiolytic / calming | Stimulating / cognitive-enhancing |
| Key neurotransmitter systems | GABA, serotonin, enkephalins | Dopamine, BDNF, serotonin |
| BDNF upregulation | Moderate | Strong |
| Anxiolytic effect | Strong (primary benefit) | Mild (secondary benefit) |
| Cognitive stimulation | Moderate (supports focus via anxiety reduction) | Strong (direct dopaminergic enhancement) |
| Immunomodulation | Significant (tuftsin-derived) | Minimal |
| Sedation risk | None | None |
| Overstimulation risk | None | Possible at high doses |
| Clinical approval (Russia) | Anxiolytic / nootropic | Nootropic / neuroprotective |
| Best suited for | Anxious individuals, stress relief | Cognitive performance, focus, motivation |
Because Selank and Semax target complementary neurochemical systems, they are frequently stacked together. The combination provides simultaneous anxiety reduction (Selank) and cognitive stimulation (Semax), resulting in a state that users describe as calm, focused, and mentally sharp. This stack is one of the most popular peptide nootropic combinations and is discussed further in the stacks section below. For a detailed profile of Semax, see our Semax nootropic profile and Semax guide.
Selank has demonstrated an excellent safety profile across both preclinical toxicology studies and clinical trials conducted in Russia. It is classified as a "practically non-toxic" substance, with an LD50 in animal studies that is several hundred times higher than the therapeutic dose. The absence of sedation, motor impairment, and dependence liability distinguishes it markedly from benzodiazepines and places it in a favourable safety category among anxiolytic agents.
Selank occupies a regulatory grey area in the United Kingdom. It is not approved as a medicine by the MHRA, meaning it cannot be prescribed, marketed, or sold as a pharmaceutical product for the treatment of any condition. However, it is also not listed as a controlled substance under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016 (peptides are generally excluded from the latter's scope, which targets substances that produce psychoactive effects by stimulating or depressing the central nervous system, as the Act includes exemptions for substances that are not ordinarily consumed for their psychoactive properties).
In practical terms, this means that Selank can be legally purchased for personal use or research purposes from peptide suppliers, but it cannot be sold with therapeutic claims or marketed as a treatment for any medical condition. UK-based consumers typically obtain Selank from online peptide research companies that sell it labelled "for research use only." The quality and purity of such products can vary, making it essential to source from reputable suppliers who provide third-party certificates of analysis (CoA) verifying the identity and purity of the peptide.
Individuals considering Selank should be aware that using an unregulated peptide carries inherent risks related to product quality, accurate dosing, and the absence of medical oversight. It is strongly advisable to discuss peptide use with a healthcare professional, particularly for those with existing medical conditions or who are taking other medications. For a broader overview of the regulatory landscape for nootropics in the United Kingdom, see our guide to nootropics in the UK.
Selank may be a suitable consideration for several groups of individuals, based on the available evidence and its pharmacological profile. However, it is important to emphasise that Selank is not a first-line treatment for any condition in Western medicine, and it should not replace evidence-based treatments such as cognitive behavioural therapy (CBT), SSRIs, or professional psychiatric care.
Selank is not recommended for the following groups:
Selank's calming, anxiolytic profile makes it an excellent foundation for nootropic stacks, particularly when combined with compounds that complement its mechanisms. The following stacks are based on pharmacological rationale and commonly reported user experiences.
This is the most popular and well-known peptide nootropic stack. Semax provides dopaminergic cognitive stimulation and strong BDNF upregulation, while Selank provides GABAergic calming and serotonin stabilisation. The result is a balanced state of alert, focused calm - cognitive enhancement without the jitteriness or anxiety that stimulating nootropics can produce, and anxiolysis without the mental sluggishness of sedating agents. Both peptides are administered as nasal sprays and can be used simultaneously. A typical protocol involves Selank 200-400 mcg per nostril and Semax 200-600 mcg per nostril, both 1-2 times daily.
L-Theanine is a naturally occurring amino acid found in tea that promotes relaxation through GABAergic and glutamatergic modulation. Combining L-Theanine (100-200 mg) with Selank creates a double anxiolytic stack that addresses anxiety through complementary mechanisms. L-Theanine also increases alpha brainwave activity, promoting a state of relaxed alertness that pairs well with Selank's calming clarity. This stack is particularly suited to individuals who find Selank alone insufficient for managing anxiety and who want an additional, well-tolerated anxiolytic layer without resorting to pharmaceutical options.
Bacopa Monnieri is an Ayurvedic herb with strong evidence for improving memory consolidation through serotonergic and cholinergic mechanisms. Pairing Bacopa (300 mg standardised to 50% bacosides, taken daily with food) with Selank creates a stack that addresses both anxiety and memory - a common combination of concerns, particularly in students and professionals facing demanding cognitive workloads. Bacopa's slow-building memory benefits (typically apparent after 8-12 weeks of consistent use) complement Selank's more rapidly onset anxiolytic effects, providing both immediate and long-term benefits.
Lion's Mane (Hericium erinaceus) is a medicinal mushroom that stimulates nerve growth factor (NGF) synthesis, supporting neurogenesis and neuroprotection. Combined with Selank's BDNF upregulation, this stack provides a broad neurotrophic support profile - both BDNF and NGF are enhanced, promoting neuroplasticity, synaptic health, and cognitive resilience from complementary angles. A typical protocol is Lion's Mane 500-1,000 mg daily (standardised extract) alongside standard Selank dosing. This stack is well suited for individuals interested in long-term brain health and neuroprotection alongside anxiety management.
Selank stands as one of the most thoroughly researched peptide nootropics available, with a pharmacological profile that uniquely bridges anxiolysis, cognitive enhancement, and immune modulation. Its multi-target mechanism of action - encompassing GABAergic enhancement, serotonin metabolism stabilisation, BDNF upregulation, enkephalin preservation, and tuftsin-derived immunomodulation - provides a breadth of neuropsychiatric benefit that single-target drugs cannot match. The clinical evidence from Russian research demonstrates anxiolytic efficacy comparable to benzodiazepines without the sedation, cognitive impairment, or dependence that makes benzodiazepine therapy problematic for long-term use.
However, it is essential to maintain appropriate perspective. Selank's evidence base, while substantial by peptide nootropic standards, does not meet the rigorous requirements of Western regulatory agencies. Most clinical data comes from Russian studies that have not been independently replicated in large-scale Western trials. The compound remains unregistered in the UK and most other Western countries, and its legal status places it in a grey area that requires careful navigation. Individuals considering Selank should source it from reputable suppliers, follow established dosing protocols, and ideally discuss its use with a knowledgeable healthcare professional.
For those who proceed with informed caution, Selank offers a compelling option for managing anxiety while preserving - and potentially enhancing - cognitive function. Its favourable safety profile, absence of dependence liability, and complementary immune-supporting properties make it a noteworthy compound in the modern nootropic landscape. For a full profile of Selank's properties and mechanisms, see our Selank nootropic profile.
Selank is a synthetic peptide developed in Russia based on the naturally occurring immunomodulatory peptide tuftsin. It has anxiolytic (anxiety-reducing) and nootropic (cognitive-enhancing) properties. Selank works by modulating GABA, serotonin, and BDNF signalling in the brain, producing a calming effect without sedation while simultaneously supporting focus and memory. It is typically administered as a nasal spray.
Selank occupies a grey area in UK law. It is not a controlled substance under the Misuse of Drugs Act, but it is not approved as a medicine or food supplement by the MHRA or FSA. It is not covered by the Psychoactive Substances Act 2016 as peptides are generally exempt. Purchasing for personal research or use is not explicitly prohibited, but it cannot be legally sold for human consumption in the UK. Always check current regulations before purchasing.
Both are Russian-developed peptide nootropics administered as nasal sprays, but they have different primary effects. Selank is primarily anxiolytic - its main strength is reducing anxiety while providing mild cognitive enhancement. Semax is primarily nootropic - it strongly upregulates BDNF and NGF for cognitive enhancement, with milder anxiolytic effects. Some users combine both for a comprehensive anxiety-reduction and cognitive-enhancement approach.
The standard Selank dosage is 250 to 500 mcg per administration, delivered as a nasal spray, taken 1 to 3 times daily. In Russian clinical practice, treatment courses typically last 14 to 21 days, followed by a break of equal length. Some users report sustained benefits at lower doses (250 mcg once or twice daily). Effects are typically noticed within 15 to 30 minutes of administration and last several hours.
Selank has a very favourable side effect profile in clinical research. Russian clinical trials report minimal adverse effects, with occasional mild nasal irritation from the spray delivery method. Unlike benzodiazepines, Selank does not cause sedation, cognitive impairment, or dependency. It does not appear to produce tolerance with regular use. However, long-term safety data in Western populations is limited, and quality control of grey-market peptides is a concern.